Scpharmaceuticals INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
scPharmaceuticals Inc. announces FDA approval for expanded FUROSCIX indication, positive financial results, and progress on autoinjector development.
scPharmaceuticals Inc.'s 2023 annual report highlights the commercial launch of FUROSCIX, positive FDA feedback on pipeline expansion, and financial results reflecting ongoing investment in growth.